Page 6 - Maky Zanganeh News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)

Phase III Study Designed to Establish the Effect of Ivonescimab in Lung Cancer Patients Whose Tumors Progressed after EGFR-TKI Therapy . | May 9, 2023

Menlo parkUnited statesUnited kingdomMaky zanganehIan andersonRobertw dugganOncologist at providence medical foundationAmerican cancer societyTeam summitWorld health organizationAkeso incSummit therapeutic mission statementSummit therapeutics incSummit therapeuticsUnited states basedMedical oncologist

Summit Therapeutics Announces Initial Indications for Clinical Trials for Ivonescimab (SMT112)

Studies Designed in Alignment with Feedback from FDA Company to Host Q1 Earnings Call on May 11, 2023 at 9:00am ET . | May 3, 2023

Menlo parkUnited statesUnited kingdomMaky zanganehRobertw dugganTeam summitCompany onDrug administrationAkeso incSummit therapeutics incSummit therapeutic mission statementSummit therapeuticsChief executive officerNasdaq global marketSummit therapeutics inc stock exchangePress release

Summit Therapeutics Inc (NASDAQ:SMMT) Q4 2022 Earnings Call Transcript

Operator: Ladies and gentlemen, thank you for standing by. My name is Brent, and I will be your conference operator today.

United statesHong kongAnkur dhingraCrown biosciencesMichelle xiaMaky zanganehBob dugganDave gancarzCelera genomicsTeam summitSummit therapeutics incSummit therapeuticsCall transcript marchSummit fourth quarterSenior vice presidentCorporate strategy

Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering

Summit Therapeutics Closes Fully-Subscribed $500 Million Rights Offering
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesMenlo parkMaky zanganehRobertw dugganDave gancarzDrug administrationTeam summitSummit therapeutic mission statementAkeso incExchange commissionCompany onSummit therapeutics incEastern timeYear endNasdaq global market

$5 billion bispecific antibody pharma collaboration

As part of a $5 billion collaboration, Akeso Inc. will out-license its PD-1-based bispecific antibody ivonescimab to Summit Therapeutics.

United statesMaky zanganehMichelle xiaAmerican society of clinical oncologyNational medical products administrationSummit therapeutics incBiopharma akeso incAkeso incAmerican societyClinical oncologyCo chief executive officer